

# H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/H8D90408445EN.html>

Date: October 2021

Pages: 57

Price: US\$ 125.00 (Single User License)

ID: H8D90408445EN

## Abstracts

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease, among others. It operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

### H. Lundbeck AS Key Recent Developments

Aug 18,2021: Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated

May 20,2021: Verantos and Lundbeck announce partnership for migraine care implementing advanced Real-World Evidence (RWE)

May 11,2021: Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is off to a good start

Mar 24,2021: Trial**Scope** chosen by H. Lundbeck to provide clinical trial disclosure services

Mar 23,2021: Lundbeck held its Annual General Meeting on 23 March 2021 as a completely electronic meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

H. Lundbeck AS - Key Facts  
H. Lundbeck AS - Key Employees  
H. Lundbeck AS - Key Employee Biographies  
H. Lundbeck AS - Major Products and Services  
H. Lundbeck AS - History  
H. Lundbeck AS - Company Statement  
H. Lundbeck AS - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
H. Lundbeck AS - Business Description  
Product Category: Abilify Maintena  
Overview  
Performance  
Product Category: Brintellix/Trintellix  
Overview  
Performance  
Product Category: CipraleX/Lexapro  
Overview  
Performance  
Product Category: Effects from Hedging  
Performance  
Product Category: Northera  
Overview  
Performance  
Product Category: Onfi  
Overview  
Performance  
Product Category: Other pharmaceuticals  
Performance  
Product Category: Other Revenue  
Performance

Product Category: Rexulti

Overview

Performance

Product Category: Sabril

Overview

Performance

Product Category: Vyepiti

Overview

Performance

Geographical Segment: Europe

Target Markets

Performance

Geographical Segment: International Markets

Target Markets

Performance

Geographical Segment: North America

Performance

R&D Overview

H. Lundbeck AS - Corporate Strategy

H. Lundbeck AS - SWOT Analysis

SWOT Analysis - Overview

H. Lundbeck AS - Strengths

H. Lundbeck AS - Weaknesses

H. Lundbeck AS - Opportunities

H. Lundbeck AS - Threats

H. Lundbeck AS - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
H. Lundbeck AS, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Aug 18, 2021: Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated

May 20, 2021: Verantos and Lundbeck announce partnership for migraine care implementing advanced Real-World Evidence (RWE)

May 11, 2021: Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is off to a good start

Mar 24, 2021: TrialScope chosen by H. Lundbeck to provide clinical trial disclosure services

Mar 23, 2021: Lundbeck held its Annual General Meeting on 23 March 2021 as a completely electronic meeting

Mar 17, 2021: Lundbeck appoints Dr. Tarek Samad as Head of Research

Mar 12, 2021: Lundbeck – New member proposed for election to Board of Directors

Feb 04, 2021: In an unprecedented year, Lundbeck delivers sales growth of 4% and core EBIT of DKK 4.4 billion

Jan 29, 2021: Lundbeck and Better Energy ensures the construction of a new solar park

Jan 12, 2021: Rigshospitalet and Lundbeck announce partnership to find new ways to treat brain diseases

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

H. Lundbeck AS, Key Facts  
H. Lundbeck AS, Key Employees  
H. Lundbeck AS, Key Employee Biographies  
H. Lundbeck AS, Major Products and Services  
H. Lundbeck AS, History  
H. Lundbeck AS, Subsidiaries  
H. Lundbeck AS, Key Competitors  
H. Lundbeck AS, Ratios based on current share price  
H. Lundbeck AS, Annual Ratios  
H. Lundbeck AS, Annual Ratios (Cont...1)  
H. Lundbeck AS, Annual Ratios (Cont...2)  
H. Lundbeck AS, Interim Ratios  
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
H. Lundbeck AS, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

H. Lundbeck AS, Performance Chart (2016 - 2020)

H. Lundbeck AS, Ratio Charts

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/H8D90408445EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8D90408445EN.html>